Establishment Labs Holdings Inc. (NASDAQ:ESTA – Free Report) – Research analysts at B. Riley reduced their Q3 2023 earnings per share (EPS) estimates for shares of Establishment Labs in a report released on Wednesday, August 9th. B. Riley analyst N. Chatterji now expects that the company will post earnings of ($0.71) per share for the quarter, down from their previous estimate of ($0.68). The consensus estimate for Establishment Labs’ current full-year earnings is ($2.56) per share. B. Riley also issued estimates for Establishment Labs’ Q4 2023 earnings at ($0.70) EPS, FY2023 earnings at ($2.56) EPS and FY2024 earnings at ($1.28) EPS.
Other research analysts have also issued research reports about the company. Mizuho increased their price target on Establishment Labs from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, April 21st. Citigroup began coverage on Establishment Labs in a research report on Thursday, June 29th. They issued a “buy” rating and a $79.00 target price on the stock. BTIG Research increased their target price on Establishment Labs from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, April 17th. Finally, Stephens reaffirmed an “overweight” rating and issued a $89.00 target price on shares of Establishment Labs in a research report on Friday, July 21st. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Establishment Labs has a consensus rating of “Buy” and a consensus target price of $98.00.
Establishment Labs Stock Performance
Shares of NASDAQ:ESTA opened at $55.76 on Friday. The business’s fifty day moving average price is $67.36 and its two-hundred day moving average price is $68.78. The stock has a market cap of $1.44 billion, a PE ratio of -22.85 and a beta of 1.01. Establishment Labs has a one year low of $44.03 and a one year high of $79.88.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. GPS Wealth Strategies Group LLC purchased a new position in Establishment Labs during the 2nd quarter worth approximately $25,000. BNP Paribas Arbitrage SA grew its position in Establishment Labs by 3,244.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company’s stock worth $41,000 after purchasing an additional 584 shares in the last quarter. Lazard Asset Management LLC grew its position in Establishment Labs by 104.5% during the 1st quarter. Lazard Asset Management LLC now owns 963 shares of the company’s stock worth $64,000 after purchasing an additional 492 shares in the last quarter. Deutsche Bank AG purchased a new position in Establishment Labs during the 4th quarter worth approximately $66,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Establishment Labs during the 4th quarter worth approximately $69,000. Institutional investors and hedge funds own 71.60% of the company’s stock.
About Establishment Labs
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Recommended Stories
- Five stocks we like better than Establishment Labs
- Investing in Blue-Chip Stocks
- Investing in Coffee: 3 Great Strategies to Consider
- How to Most Effectively Use the MarketBeat Earnings Screener
- 5 Best Stocks to Buy in a Bear Market
- ETF Screener: Uses and Step-by-Step Guide
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
